Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophageal Neoplasms | 4 | 2023 | 1659 | 1.550 |
Why?
|
Data Interpretation, Statistical | 10 | 2024 | 2688 | 1.530 |
Why?
|
Proportional Hazards Models | 15 | 2022 | 12529 | 1.430 |
Why?
|
Survival Analysis | 14 | 2022 | 10086 | 1.410 |
Why?
|
Trifluridine | 2 | 2019 | 28 | 1.220 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10380 | 1.200 |
Why?
|
Hyperthermia, Induced | 2 | 2023 | 414 | 1.160 |
Why?
|
Breast Neoplasms | 14 | 2024 | 21069 | 1.130 |
Why?
|
Medical Oncology | 5 | 2023 | 2339 | 1.130 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2895 | 1.090 |
Why?
|
Rectal Neoplasms | 3 | 2021 | 1183 | 1.060 |
Why?
|
Stomach Neoplasms | 3 | 2021 | 1469 | 1.020 |
Why?
|
Esophagectomy | 3 | 2023 | 478 | 0.900 |
Why?
|
Lung Neoplasms | 9 | 2022 | 13446 | 0.870 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2024 | 57 | 0.870 |
Why?
|
Oxadiazoles | 2 | 2020 | 94 | 0.850 |
Why?
|
Muscular Dystrophy, Duchenne | 3 | 2021 | 271 | 0.840 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8037 | 0.830 |
Why?
|
Drug-Eluting Stents | 2 | 2019 | 680 | 0.830 |
Why?
|
Cardiovascular Diseases | 12 | 2023 | 15645 | 0.820 |
Why?
|
Humans | 135 | 2024 | 765926 | 0.810 |
Why?
|
Research Design | 7 | 2024 | 6204 | 0.810 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5379 | 0.800 |
Why?
|
Nose Neoplasms | 1 | 2024 | 249 | 0.760 |
Why?
|
Immunotherapy | 6 | 2024 | 4746 | 0.740 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6503 | 0.730 |
Why?
|
Neoplasms | 10 | 2022 | 22340 | 0.730 |
Why?
|
Treatment Outcome | 28 | 2024 | 65194 | 0.710 |
Why?
|
Survival Rate | 10 | 2021 | 12822 | 0.680 |
Why?
|
Aromatase | 1 | 2020 | 147 | 0.660 |
Why?
|
Colonic Neoplasms | 2 | 2023 | 2530 | 0.650 |
Why?
|
Adenocarcinoma | 3 | 2023 | 6360 | 0.630 |
Why?
|
Paclitaxel | 3 | 2023 | 1726 | 0.580 |
Why?
|
Head and Neck Neoplasms | 2 | 2024 | 2924 | 0.580 |
Why?
|
Propanolamines | 1 | 2018 | 163 | 0.570 |
Why?
|
Rifampin | 1 | 2019 | 350 | 0.560 |
Why?
|
Aspirin | 3 | 2024 | 3135 | 0.560 |
Why?
|
Patient Care Management | 1 | 2020 | 301 | 0.560 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2018 | 1238 | 0.560 |
Why?
|
Epoetin Alfa | 1 | 2016 | 78 | 0.540 |
Why?
|
Blood Pressure Determination | 2 | 2023 | 646 | 0.530 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2022 | 1142 | 0.520 |
Why?
|
Lymph Node Excision | 2 | 2023 | 1258 | 0.520 |
Why?
|
Taxoids | 2 | 2018 | 665 | 0.520 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2024 | 4044 | 0.510 |
Why?
|
Anticholesteremic Agents | 2 | 2020 | 970 | 0.500 |
Why?
|
Digestive System Surgical Procedures | 1 | 2021 | 581 | 0.500 |
Why?
|
Hypertension | 5 | 2023 | 8616 | 0.490 |
Why?
|
Therapeutics | 1 | 2015 | 113 | 0.490 |
Why?
|
Axilla | 1 | 2018 | 615 | 0.490 |
Why?
|
Endpoint Determination | 4 | 2024 | 591 | 0.480 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 713 | 0.480 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11858 | 0.470 |
Why?
|
Prostatic Neoplasms | 4 | 2022 | 11090 | 0.460 |
Why?
|
Urologic Neoplasms | 1 | 2017 | 312 | 0.430 |
Why?
|
Statistics as Topic | 3 | 2020 | 2350 | 0.430 |
Why?
|
Polydeoxyribonucleotides | 2 | 2024 | 136 | 0.430 |
Why?
|
Receptor, erbB-2 | 5 | 2024 | 2592 | 0.420 |
Why?
|
Confidence Intervals | 3 | 2020 | 2915 | 0.420 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3109 | 0.400 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3231 | 0.400 |
Why?
|
Vascular Diseases | 1 | 2020 | 1161 | 0.400 |
Why?
|
Standard of Care | 1 | 2016 | 568 | 0.390 |
Why?
|
Drug Therapy | 1 | 2015 | 504 | 0.390 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2325 | 0.370 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 3183 | 0.370 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2004 | 0.360 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 6958 | 0.360 |
Why?
|
Neoplasms, Second Primary | 1 | 2019 | 1056 | 0.360 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2024 | 878 | 0.360 |
Why?
|
Longitudinal Studies | 4 | 2024 | 14745 | 0.360 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 3542 | 0.360 |
Why?
|
Statistical Distributions | 1 | 2010 | 60 | 0.360 |
Why?
|
Bone Density Conservation Agents | 1 | 2018 | 791 | 0.350 |
Why?
|
Quinolines | 1 | 2016 | 769 | 0.350 |
Why?
|
Biometry | 2 | 2010 | 571 | 0.340 |
Why?
|
Pandemics | 2 | 2020 | 8721 | 0.340 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1943 | 0.340 |
Why?
|
Soft Tissue Neoplasms | 1 | 2019 | 1163 | 0.330 |
Why?
|
Multicenter Studies as Topic | 4 | 2024 | 1729 | 0.330 |
Why?
|
Kidney Neoplasms | 2 | 2024 | 4278 | 0.330 |
Why?
|
Melanoma | 2 | 2018 | 5695 | 0.330 |
Why?
|
Carcinoma | 1 | 2020 | 2311 | 0.320 |
Why?
|
Antihypertensive Agents | 5 | 2023 | 2028 | 0.320 |
Why?
|
Adiposity | 1 | 2019 | 1891 | 0.310 |
Why?
|
Consensus | 1 | 2018 | 3202 | 0.310 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5836 | 0.310 |
Why?
|
Thymine | 2 | 2019 | 69 | 0.300 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4349 | 0.300 |
Why?
|
Dementia | 2 | 2021 | 2741 | 0.300 |
Why?
|
Heart Failure | 7 | 2024 | 11837 | 0.290 |
Why?
|
Thiazolidinediones | 1 | 2011 | 459 | 0.290 |
Why?
|
Sarcoma | 1 | 2019 | 1799 | 0.290 |
Why?
|
Aminopyridines | 2 | 2022 | 576 | 0.290 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3637 | 0.280 |
Why?
|
Laparoscopy | 1 | 2019 | 2037 | 0.280 |
Why?
|
MicroRNAs | 1 | 2023 | 3788 | 0.280 |
Why?
|
Sample Size | 3 | 2015 | 843 | 0.280 |
Why?
|
Acute Coronary Syndrome | 1 | 2020 | 2185 | 0.270 |
Why?
|
Tuberculosis | 1 | 2019 | 2009 | 0.270 |
Why?
|
Pyrrolidines | 2 | 2019 | 337 | 0.270 |
Why?
|
Benzimidazoles | 2 | 2022 | 862 | 0.260 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4904 | 0.250 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1883 | 0.250 |
Why?
|
Multiple Myeloma | 2 | 2024 | 5189 | 0.240 |
Why?
|
Time Factors | 10 | 2024 | 40097 | 0.240 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6838 | 0.240 |
Why?
|
Area Under Curve | 2 | 2018 | 1637 | 0.220 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2020 | 2769 | 0.220 |
Why?
|
Patient Selection | 1 | 2015 | 4248 | 0.220 |
Why?
|
Antineoplastic Agents | 4 | 2024 | 13631 | 0.220 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 3106 | 0.210 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9065 | 0.210 |
Why?
|
Drug Combinations | 2 | 2019 | 2075 | 0.200 |
Why?
|
Female | 29 | 2024 | 396141 | 0.190 |
Why?
|
Nasal Cavity | 1 | 2024 | 309 | 0.190 |
Why?
|
Myocardial Infarction | 4 | 2021 | 11508 | 0.190 |
Why?
|
Models, Statistical | 6 | 2024 | 5088 | 0.190 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5450 | 0.190 |
Why?
|
Cause of Death | 2 | 2019 | 3715 | 0.180 |
Why?
|
Double-Blind Method | 5 | 2019 | 12417 | 0.180 |
Why?
|
Prostate-Specific Antigen | 2 | 2022 | 2463 | 0.180 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 206 | 0.180 |
Why?
|
Risk Assessment | 5 | 2019 | 24275 | 0.180 |
Why?
|
Liver Cirrhosis, Biliary | 2 | 2012 | 108 | 0.170 |
Why?
|
Models, Theoretical | 1 | 2012 | 3560 | 0.170 |
Why?
|
Neoplasm Staging | 3 | 2024 | 11196 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9373 | 0.170 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5752 | 0.170 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2023 | 287 | 0.170 |
Why?
|
Placebos | 1 | 2024 | 1659 | 0.170 |
Why?
|
Stroke | 1 | 2022 | 9739 | 0.170 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 6544 | 0.170 |
Why?
|
Fallopian Tubes | 1 | 2020 | 179 | 0.170 |
Why?
|
Lymph Nodes | 2 | 2023 | 3447 | 0.160 |
Why?
|
Piperazines | 2 | 2021 | 2546 | 0.160 |
Why?
|
Bryostatins | 1 | 2019 | 24 | 0.160 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2019 | 28 | 0.160 |
Why?
|
Eosinophils | 1 | 2024 | 946 | 0.160 |
Why?
|
Codon, Nonsense | 1 | 2020 | 288 | 0.160 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9239 | 0.160 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 291 | 0.160 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.160 |
Why?
|
Blood Pressure | 4 | 2023 | 8530 | 0.150 |
Why?
|
Hormones | 1 | 2022 | 865 | 0.150 |
Why?
|
Phthalazines | 1 | 2021 | 397 | 0.150 |
Why?
|
Immunization, Passive | 1 | 2020 | 616 | 0.150 |
Why?
|
Isoniazid | 1 | 2019 | 279 | 0.150 |
Why?
|
Alanine | 1 | 2020 | 613 | 0.140 |
Why?
|
Cisplatin | 1 | 2023 | 1654 | 0.140 |
Why?
|
Asthma | 1 | 2016 | 6268 | 0.140 |
Why?
|
Simvastatin | 1 | 2020 | 345 | 0.140 |
Why?
|
Anastomosis, Surgical | 1 | 2021 | 992 | 0.140 |
Why?
|
Intensive Care Units | 2 | 2021 | 3799 | 0.140 |
Why?
|
Stents | 2 | 2019 | 3191 | 0.140 |
Why?
|
Neoplasm Invasiveness | 2 | 2024 | 3599 | 0.140 |
Why?
|
Nitriles | 1 | 2022 | 981 | 0.140 |
Why?
|
Computer Simulation | 2 | 2024 | 6251 | 0.140 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2019 | 284 | 0.140 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2020 | 419 | 0.140 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2019 | 344 | 0.140 |
Why?
|
Hepatitis B, Chronic | 2 | 2014 | 413 | 0.140 |
Why?
|
Absorbable Implants | 1 | 2019 | 333 | 0.140 |
Why?
|
Republic of Korea | 1 | 2019 | 583 | 0.140 |
Why?
|
Male | 22 | 2024 | 363815 | 0.130 |
Why?
|
Uracil | 1 | 2018 | 210 | 0.130 |
Why?
|
Random Allocation | 1 | 2021 | 2394 | 0.130 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2023 | 781 | 0.130 |
Why?
|
Pravastatin | 1 | 2018 | 391 | 0.130 |
Why?
|
Positive-Pressure Respiration | 1 | 2021 | 712 | 0.130 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 518 | 0.130 |
Why?
|
Monte Carlo Method | 2 | 2012 | 1238 | 0.130 |
Why?
|
Observation | 1 | 2017 | 309 | 0.130 |
Why?
|
Indazoles | 1 | 2017 | 303 | 0.120 |
Why?
|
Albuterol | 1 | 2016 | 211 | 0.120 |
Why?
|
Prognosis | 4 | 2019 | 29890 | 0.120 |
Why?
|
Adrenergic beta-Agonists | 1 | 2016 | 345 | 0.120 |
Why?
|
Probability | 1 | 2020 | 2474 | 0.120 |
Why?
|
Deoxycytidine | 1 | 2019 | 886 | 0.120 |
Why?
|
Independent Living | 1 | 2019 | 583 | 0.120 |
Why?
|
Metals | 1 | 2019 | 709 | 0.120 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2270 | 0.120 |
Why?
|
Body Composition | 2 | 2019 | 2441 | 0.110 |
Why?
|
Rectum | 1 | 2019 | 895 | 0.110 |
Why?
|
Gastrectomy | 1 | 2019 | 693 | 0.110 |
Why?
|
Hematinics | 1 | 2016 | 282 | 0.110 |
Why?
|
Histocytochemistry | 1 | 2014 | 695 | 0.110 |
Why?
|
Rare Diseases | 1 | 2019 | 629 | 0.110 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 2125 | 0.110 |
Why?
|
Administration, Inhalation | 1 | 2016 | 1154 | 0.110 |
Why?
|
Spinal Curvatures | 1 | 2014 | 74 | 0.110 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2018 | 730 | 0.110 |
Why?
|
Patient Admission | 1 | 2021 | 1365 | 0.110 |
Why?
|
Estrogens | 1 | 2020 | 1528 | 0.110 |
Why?
|
Diphosphonates | 1 | 2018 | 625 | 0.110 |
Why?
|
Braces | 1 | 2014 | 139 | 0.100 |
Why?
|
Nursing Homes | 1 | 2021 | 1084 | 0.100 |
Why?
|
Esophagus | 1 | 2019 | 1038 | 0.100 |
Why?
|
Bronchodilator Agents | 1 | 2016 | 513 | 0.100 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1104 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2022 | 1590 | 0.100 |
Why?
|
Penicillamine | 1 | 2012 | 59 | 0.100 |
Why?
|
Erythropoietin | 1 | 2016 | 716 | 0.100 |
Why?
|
Incidence | 2 | 2022 | 21513 | 0.100 |
Why?
|
Sirolimus | 1 | 2019 | 1541 | 0.100 |
Why?
|
Polymers | 1 | 2019 | 1622 | 0.100 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8522 | 0.100 |
Why?
|
Anti-Asthmatic Agents | 1 | 2016 | 572 | 0.090 |
Why?
|
Primary Prevention | 1 | 2018 | 1187 | 0.090 |
Why?
|
Hemoglobins | 1 | 2016 | 1531 | 0.090 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3930 | 0.090 |
Why?
|
Biostatistics | 1 | 2012 | 162 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1600 | 0.080 |
Why?
|
Survivors | 1 | 2020 | 2373 | 0.080 |
Why?
|
Aged | 12 | 2024 | 171163 | 0.080 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3690 | 0.080 |
Why?
|
Elasticity Imaging Techniques | 1 | 2014 | 397 | 0.080 |
Why?
|
Nonlinear Dynamics | 1 | 2012 | 490 | 0.080 |
Why?
|
Natriuretic Agents | 1 | 2009 | 57 | 0.080 |
Why?
|
Sulfonamides | 1 | 2017 | 1979 | 0.070 |
Why?
|
Bone and Bones | 1 | 2018 | 2555 | 0.070 |
Why?
|
Heart Rate | 1 | 2019 | 4203 | 0.070 |
Why?
|
Pyridines | 1 | 2019 | 2885 | 0.070 |
Why?
|
Anemia | 1 | 2016 | 1514 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6491 | 0.070 |
Why?
|
Markov Chains | 1 | 2010 | 971 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2823 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2910 | 0.070 |
Why?
|
Hepatitis C, Chronic | 1 | 2014 | 1032 | 0.070 |
Why?
|
Nucleosides | 1 | 2007 | 130 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2021 | 12235 | 0.070 |
Why?
|
Carboxypeptidases | 1 | 2006 | 121 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3592 | 0.060 |
Why?
|
Meta-Analysis as Topic | 1 | 2011 | 1366 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2024 | 637 | 0.060 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 520 | 0.060 |
Why?
|
Aortic Valve Stenosis | 1 | 2017 | 2022 | 0.060 |
Why?
|
Pyrimidines | 1 | 2017 | 3049 | 0.060 |
Why?
|
Stroke Volume | 1 | 2019 | 5595 | 0.060 |
Why?
|
Abdominal Fat | 1 | 2006 | 217 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20133 | 0.060 |
Why?
|
Naphthoquinones | 1 | 2004 | 61 | 0.060 |
Why?
|
Decision Making | 1 | 2018 | 3955 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1961 | 0.060 |
Why?
|
Exons | 1 | 2010 | 2393 | 0.060 |
Why?
|
Coronary Disease | 1 | 2018 | 5919 | 0.060 |
Why?
|
Thrombolytic Therapy | 1 | 2013 | 2050 | 0.060 |
Why?
|
Azithromycin | 1 | 2004 | 202 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2012 | 6202 | 0.050 |
Why?
|
Creatinine | 1 | 2009 | 1916 | 0.050 |
Why?
|
Peritoneal Dialysis | 1 | 2024 | 161 | 0.050 |
Why?
|
Nevirapine | 1 | 2004 | 273 | 0.050 |
Why?
|
Child | 3 | 2023 | 80568 | 0.050 |
Why?
|
Gene Frequency | 1 | 2010 | 3623 | 0.050 |
Why?
|
Linkage Disequilibrium | 1 | 2007 | 1996 | 0.050 |
Why?
|
Adult | 9 | 2024 | 223088 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2010 | 2353 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2007 | 16039 | 0.050 |
Why?
|
Algorithms | 4 | 2021 | 14064 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5691 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2004 | 663 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2004 | 663 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10810 | 0.040 |
Why?
|
Prednisolone | 1 | 2021 | 323 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2009 | 1735 | 0.040 |
Why?
|
Quality of Life | 2 | 2024 | 13463 | 0.040 |
Why?
|
HIV Infections | 3 | 2018 | 17531 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39228 | 0.040 |
Why?
|
Cholinesterase Inhibitors | 1 | 2021 | 242 | 0.040 |
Why?
|
Iceland | 1 | 2019 | 183 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2024 | 2844 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2004 | 3796 | 0.040 |
Why?
|
Middle Aged | 8 | 2024 | 223016 | 0.040 |
Why?
|
Brain | 1 | 2024 | 27179 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2004 | 1404 | 0.040 |
Why?
|
Alzheimer Disease | 1 | 2019 | 8722 | 0.030 |
Why?
|
Prospective Studies | 2 | 2019 | 54807 | 0.030 |
Why?
|
Genetic Variation | 2 | 2010 | 6612 | 0.030 |
Why?
|
Prednisone | 1 | 2021 | 1566 | 0.030 |
Why?
|
Patient Dropouts | 1 | 2019 | 411 | 0.030 |
Why?
|
Pre-Eclampsia | 1 | 2006 | 1257 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59496 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 2 | 2018 | 2586 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2004 | 1387 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 13082 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2023 | 943 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20690 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2653 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2007 | 3053 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2018 | 1899 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2227 | 0.030 |
Why?
|
Models, Genetic | 3 | 2010 | 3447 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2004 | 4780 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2004 | 2184 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2024 | 4423 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2004 | 9525 | 0.020 |
Why?
|
Gene Expression | 2 | 2018 | 7581 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7842 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8724 | 0.020 |
Why?
|
Genetic Markers | 2 | 2007 | 2603 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2019 | 2414 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3385 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2004 | 4558 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15828 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3612 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10727 | 0.020 |
Why?
|
Hepatitis B e Antigens | 1 | 2007 | 135 | 0.020 |
Why?
|
Angiotensinogen | 1 | 2006 | 161 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6409 | 0.020 |
Why?
|
Guanine | 1 | 2007 | 281 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 2004 | 4617 | 0.020 |
Why?
|
Lamivudine | 1 | 2007 | 368 | 0.020 |
Why?
|
Genetics, Population | 1 | 2010 | 943 | 0.020 |
Why?
|
Rural Health | 1 | 2006 | 301 | 0.010 |
Why?
|
Atovaquone | 1 | 2004 | 56 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2024 | 81537 | 0.010 |
Why?
|
Nelfinavir | 1 | 2004 | 68 | 0.010 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2006 | 323 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2004 | 241 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 2009 | 810 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26282 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6766 | 0.010 |
Why?
|
Interferon-alpha | 1 | 2007 | 909 | 0.010 |
Why?
|
Liver Failure, Acute | 1 | 2004 | 183 | 0.010 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2004 | 386 | 0.010 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2004 | 340 | 0.010 |
Why?
|
United States | 2 | 2024 | 72909 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13614 | 0.010 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2004 | 231 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 41680 | 0.010 |
Why?
|
Renin-Angiotensin System | 1 | 2006 | 736 | 0.010 |
Why?
|
Cognition | 1 | 2019 | 7043 | 0.010 |
Why?
|
Adenine | 1 | 2007 | 994 | 0.010 |
Why?
|
Absorptiometry, Photon | 1 | 2006 | 1707 | 0.010 |
Why?
|
HIV-1 | 1 | 2018 | 6945 | 0.010 |
Why?
|
China | 1 | 2006 | 2383 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2004 | 2172 | 0.010 |
Why?
|
Safety | 1 | 2004 | 1157 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2007 | 22228 | 0.010 |
Why?
|
Administration, Oral | 1 | 2007 | 4016 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2004 | 1739 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2004 | 2717 | 0.010 |
Why?
|
Health Surveys | 1 | 2006 | 4058 | 0.010 |
Why?
|
Rural Population | 1 | 2006 | 2318 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 6306 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2004 | 26380 | 0.010 |
Why?
|
Odds Ratio | 1 | 2006 | 9656 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 7073 | 0.010 |
Why?
|
Pregnancy | 2 | 2006 | 30230 | 0.010 |
Why?
|
Boston | 1 | 2006 | 9334 | 0.010 |
Why?
|
Sex Factors | 1 | 2006 | 10611 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74850 | 0.010 |
Why?
|
Genotype | 1 | 2006 | 13026 | 0.010 |
Why?
|
Chronic Disease | 1 | 2006 | 9351 | 0.010 |
Why?
|
Genetic Testing | 1 | 2004 | 3594 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12803 | 0.010 |
Why?
|
Age Factors | 1 | 2006 | 18382 | 0.010 |
Why?
|
Software | 1 | 2004 | 4462 | 0.010 |
Why?
|
Body Mass Index | 1 | 2006 | 13042 | 0.000 |
Why?
|
Phenotype | 1 | 2006 | 16714 | 0.000 |
Why?
|
Infant | 1 | 2004 | 36426 | 0.000 |
Why?
|
Child, Preschool | 1 | 2004 | 42510 | 0.000 |
Why?
|
Adolescent | 1 | 2004 | 88811 | 0.000 |
Why?
|